Opendata, web and dolomites

DEALS

Biomarker assay development to expedite ALS experimental therapeutic advancement

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DEALS project word cloud

Explore the words cloud of the DEALS project. It provides you a very rough idea of what is the project "DEALS" about.

als    gained    million    therapies    earlier    speeding    diagnosed    muscle    speaking    tool    eradicate    biomarkers    medicinal    symptoms    received    spasticity    25    entrepreneurs    founded    successful    onset    trials    mission    rare    designation    clinical    breathing    mainly    revenues    feasibility    14    walking    time    practical    diagnostic    2012    additional    foreseen    disease    delay    paper    slowing    deals    sclerosis    ema    soon    mostly    sme    lack    monitoring    severely    wasting    amyotrophic    lateral    perform    economic    progressive    die    benefit    drug    proof    therapeutic    respiratory    dutch    stem    detectable    treeway    diseases    orphan    moving    final    tests    instrumental    initial    speed    progression    difficulties    assay    earth    patients    assays    swallowing    efficacy    characterised    combination    excluding    symptom    therapy    quick    developer    accurate    interventions    weakness    diagnosis    market   

Project "DEALS" data sheet

The following table provides information about the project.

Coordinator
TREEWAY B.V. 

Organization address
address: SEVILLAWEG 142
city: ROTTERDAM
postcode: 3047AL
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.treeway.nl/treeway-receive-h2020-grant-for-biomarker-feasibility-study
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TREEWAY B.V. NL (ROTTERDAM) coordinator 50˙000.00

Map

 Project objective

The unique Dutch SME Treeway B.V. was founded in 2012 by two highly experienced and successful entrepreneurs that both have been diagnosed with amyotrophic lateral sclerosis (ALS). It is Treeway’s mission to eradicate ALS from the face of the earth by speeding up ALS research and bringing new therapies in the market as soon as possible. Treeway already has one new therapy in clinical development, which has recently received EMA’s Orphan Medicinal Product Designation.

ALS is a rare disease that is characterised by muscle spasticity and rapidly progressive weakness due to muscle wasting. This results in difficulties in walking, moving, speaking, swallowing, and breathing. Most ALS patients die from respiratory failure within three years. ALS diagnosis currently is mainly aimed at excluding other diseases with similar symptoms. As a result there is a 9–14-month delay between symptom onset and final diagnosis of ALS. For similar reasons, there is also a lack of accurate and practical diagnostic tests for monitoring the benefit of potential therapeutic interventions for ALS. This is severely slowing down the progression of clinical drug development in this field.

As ALS drug developer, Treeway will greatly benefit from the availability of a (combination of) quick diagnostic assay(s) to be used in monitoring therapeutic efficacy in clinical trials. In addition, the ALS diagnostic tool may also proof to be instrumental for (speeding up) the initial diagnosis of the disease.

Therefore, within DEALS, Treeway will perform a mostly paper study to investigate the technical and economic feasibility of developing a quick and reliable diagnostic tool. These developments will be based on known and detectable biomarkers of the disease. Economic benefit will stem from the ability of the assays to enable earlier diagnosis and to speed up clinical drug development; per one month gained in development time for a new ALS drug, about €25 million additional revenues can be foreseen.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DEALS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DEALS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More